ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 11, 2017

Primary Completion Date

October 18, 2018

Study Completion Date

October 18, 2018

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

Avacincaptad Pegol

Avacincaptad Pegol in combination with Lucentis

DRUG

Lucentis

Avacincaptad Pegol in combination with Lucentis

Trial Locations (28)

1076

Peterfy Sandor utcai Korhaz-Rendelointezet es Baleseti Kozpont, Budapest

1133

Budapest Retina Associates, Budapest

6702

Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Szemeszeti Klinika, Szeged

13224

Retina Vitreous Surgeons of CNY, PC, Syracuse

19107

Mid Atlantic Retina, Philadelphia

29456

Charleston Neuroscience Institute, Ladson

32701

Florida Eye Clinic, Altamonte Springs

32901

Florida Eye Associates, Melbourne

55435

VitreoRetinal Surgery, Minneapolis

61615

Illinois Eye Center, Peoria

67214

Vitreo Retinal Consultants & Surgeons, Wichita

76087

Strategic Clinical Research Group, Willow Park

79606

Retina Research Institute of Texas, Abilene

80214

Colorado Retina Associates, Golden

85053

Retinal Research Institute, Phoenix

85704

Retina Centers PC, Tucson

85710

Retina Associates SW, PC, Tucson

89052

Retina Consultants of Nevada, Henderson

89502

Sierra Eye Associates, Reno

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

92374

Retina Consultants of Southern California, Redlands

92705

Orange County Retina Medical Group, Santa Ana

92835

Retina Consultants of Orange County, Fullerton

95841

Retinal Consultants Medical Group, Sacramento

97221

Retina Northwest PC, Portland

02114

Ophthalmic Consultants of Boston, Boston

LV-1002

Pauls Stradins Clinical University Hospital, Clinic of Ophthalmology, Riga

LV-1050

Dr. Solomatin's eye rehabilitation and vision correction centre, Riga

Sponsors
All Listed Sponsors
lead

Ophthotech Corporation

INDUSTRY

NCT03362190 - ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD) | Biotech Hunter | Biotech Hunter